GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » 10-Year ROIIC %

Athersys (Athersys) 10-Year ROIIC % : -422.35% (As of Dec. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Athersys 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Athersys's 10-Year ROIIC % for the quarter that ended in Dec. 2022 was -422.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Athersys's 10-Year ROIIC % or its related term are showing as below:

ATHXQ's 10-Year ROIIC % is ranked worse than
84.29% of 1362 companies
in the Biotechnology industry
Industry Median: -34.68 vs ATHXQ: -422.35

Athersys 10-Year ROIIC % Historical Data

The historical data trend for Athersys's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys 10-Year ROIIC % Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -180.84 752.09 -8,633.20 -411.91 -422.35

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -422.35 - - -

Competitive Comparison of Athersys's 10-Year ROIIC %

For the Biotechnology subindustry, Athersys's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Athersys's 10-Year ROIIC % falls into.



Athersys 10-Year ROIIC % Calculation

Athersys's 10-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -77.009 (Dec. 2022) - -16.001 (Dec. 2012) )/( 16.566 (Dec. 2022) - 2.121 (Dec. 2012) )
=-61.008/14.445
=-422.35%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Athersys  (OTCPK:ATHXQ) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Athersys 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Athersys's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115